Peak Bio's management team has combined 50 years of industry experience in small molecules, antibodies, and antibody-drug-conjugates (ADC). The company is developing a differentiated Trop2 PH1 ADC and investigating collaborations for clinical development and commercialization of this asset along with other collaboration opportunities incorporating novel payloads.
Cyborg Score Rationale
Peak Bio is a clinical-stage biotech with experienced management and a focused pipeline in oncology and inflammation. However, the company is pre-revenue with limited operational scale and has recently undergone significant corporate restructuring via merger discussions as of late 2024.
Top Insights
Lead product PHP-303 is a 5th generation neutrophil elastase inhibitor for Alpha1 anti-trypsin deficiency disorder (AATD).
In November 2024, Akari Therapeutics shareholders approved a merger with Peak Bio, Inc.
As of June 2025, Peak Bio has approximately 35 employees across 4 continents.
Peak Bio was founded in 2015.
Named Competitors
Dana Point Therapeutics — Biopharmaceutical company focused on oncology